Five years of local control of subscapularis aggressive fibromatosis managed by surgery and imatinib: a case report

Dao, Abou; Benchakroun, Nadia; Jabir, H.; Taleb, Amina; Bouchbika, Zineb; Tawfiq, N.; Jouhadi, H.; Sahraoui, S.; Benider, Abdellatif

doi:10.1186/1752-1947-8-416

Cited by 4 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18,129,130,141,[145][146][147]168,169 Tyrosine kinase inhibitors also have activity in some DTF cases, and meaningful responses have been described. 64,155,156,[169][170][171][172][173][174] In at least 1 case the tumor was responsive to sunitinib but not imatinib at the usual doses, 169 suggesting that in some cases efficacy may be due to effects on targets other than KIT (kit proto-oncogene receptor tyrosine kinase). (Table).…”

Section: Evidence For Clinical Treatments Of Dtfmentioning

confidence: 99%

Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor

Skubitz

2017

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Aggressive fibromatosis, also known as desmoid-type fibromatosis (DTF) or desmoid tumor, is an uncommon locally invasive tumor. Because of its low incidence and variable behavior, DTF is often first seen by physicians who are not familiar with it, and recent advances in understanding this disease have led to changes in treatment approaches. The Wnt (β-catenin) pathway appears to play a key role in DTF pathogenesis, and recent studies of DTF biology suggest a possible model of DTF pathogenesis. Histologically, DTF shows a poorly circumscribed proliferation of myofibroblast-like cells with variable collagen deposition, similar to the proliferative phase of wound healing, and DTF has been associated with trauma and pregnancy. Desmoid-type fibromatosis may be a useful model of the tumor stroma in carcinomas as well as other fibrosing diseases such as progressive pulmonary fibrosis. The clinical course of DTF can vary greatly among patients, complicating the determination of the optimal treatment approach. Treatment options include surgery, nonsteroidal anti-inflammatory drugs with or without hormonal manipulation, chemotherapy, radiation therapy, and other forms of local therapy. Many treatments have been used, but these are not without toxicities. Because of the variable nature of the disease and the potential morbidity of treatment, some cases of DTF may do better without treatment; simple observation is often the best initial treatment. This review used a PubMed search from January 1, 1980, through October 31, 2016, using the terms fibromatosis and desmoid and discusses DTF disease characteristics, pathophysiology, and treatment options as well as examines several cases illustrating key points in the biology and treatment of this heterogeneous disease.

show abstract

Section: Evidence For Clinical Treatments Of Dtfmentioning

confidence: 99%

Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor

Skubitz

2017

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…Imatinib was the primary drug administered for DF. Additionally, case reports indicated that imatinib exhibited no discernible toxic effects and notably alleviated patient discomfort ( 28 ). In cases of imatinib resistance, sunitinib serves as a viable alternative.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis

Xie,

Huang,

Gong

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

IntroductionDesmoid fibromatosis is an aggressive fibroblastic neoplasm with a high propensity for local recurrence. Targeted therapy for Desmoid fibromatosis represents a novel avenue in systemic treatment. Anlotinib, a novel multitargeted angiogenesis inhibitor, represents a novel approach for targeted therapy. Therefore, this study aims to assess the efficacy and safety of anlotinib in patients with Desmoid fibromatosis.MethodsWe retrospectively gathered the clinical medical records of Desmoid fibromatosis patients who underwent anlotinib treatment between June 2019 and November 2023 at our center. Anlotinib was initiated at a daily dose of 12 mg and adjusted based on drug-related toxicity. Tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors 1.1 criteria. Progression-free survival served as the primary endpoint and was analyzed utilizing the Kaplan–Meier method.ResultsIn total, sixty-six consecutive patients were enrolled. No patients achieved a complete response; however, fourteen patients (21.21%) exhibited a partial response, while forty-six patients (70%) experienced disease stability. Progressive disease was observed in 6 patients (9.10%), and the progression-free survival rates at 12 and 36months were 89.71% and 82.81%, respectively. The disease control rate was 90.91%, while the objective response rate was 21.21%.ConclusionAnlotinib proves effective in managing recurrent and symptomatic patients with Desmoid fibromatosis. However, the toxicity profile of anlotinib presents a higher risk of Hand-Foot Skin Reaction and hypertension. Therefore, given that 41.67% of patients were subjected to dose adjustments associated with the initial dose of 12 mg, implementing dosage reductions may help balance efficacy with side effects.

show abstract

“…Invasive bromatosis has no signs of malignancy in cytological morphology, no lymphatic and blood tract metastasis, but it is invasive, recurring, and locally destructive, which is different from benign and malignant tumors [1][2][3][4] . WHO (1994) de nes it as differentiated broblast tumors, whose biological characteristics are between benign broblast tumors and brosarcomas, and are recognized by more and more scholars [5][6][7][8] . Primary invasive bromatosis of the stomach is rare.…”

Section: Introductionmentioning

confidence: 99%

Histopathological Features and Immunophenotype of Primary Gastric Invasive Fibromatosis

Wang¹,

Zhang²,

Jiang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background To investigate the histopathological characteristics, immunophenotype and differential diagnosis of primary gastric invasive fibromatosis.Methods The clinical manifestations, histological morphology and immunophenotype of 4 cases of primary gastric invasive fibromatosis were observed and related literatures were reviewed.Results Among the 4 patients, 2 were males and 2 were females, aged 28 and 47 years, respectively. The lesions were located in the stomach in 2 cases, the gastric antrum in 1 case and cardia in 1 case. Under the microscope, the tumor was located in the submucosa, growing infiltratingly, and infiltrating into the gastric wall muscularis, serous membrane and extraserous fatty tissue. Tumor cells were rich in cytoplasm, with unclear cell boundaries, long rod-shaped nuclei, deep chromatin, no atypia, and rare mitotic figures. The tumor tissue was composed of proliferating spindle-shaped fibroblasts and collagen fibers, and the cell morphology was relatively uniform, arranged in parallel bundles or staggered weaves. Tumor tissue invaded and destroyed smooth muscle, blood vessels, nerve tissue and adipose tissue of the gastric wall. Immunophenotype: positive expression of vimentin, β-catenin, SMA positive expression; CKpan, EMA, S-100 protein, desmin, CD99, Bcl-2, ALK, CD34, CD117, DOG1, hormone receptors were all negative; The cell proliferation index ki-67 positive cells were 3–5%.Conclusion Primary invasive fibromatosis of the stomach is a relatively rare spindle cell tumor, which needs to be differentiated from tumors and pathological lesions such as inflammatory myofibroblastic tumor, plexiform mucinous fibroma, gastrointestinal stromal tumor, etc.

show abstract

Five years of local control of subscapularis aggressive fibromatosis managed by surgery and imatinib: a case report

Cited by 4 publications

References 12 publications

Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor

Biology and Treatment of Aggressive Fibromatosis or Desmoid Tumor

Efficacy and safety of anlotinib in patients with desmoid fibromatosis: a retrospective analysis

Histopathological Features and Immunophenotype of Primary Gastric Invasive Fibromatosis

Contact Info

Product

Resources

About